Funding Partners

Funding Partners

CARB-X is a non-profit partnership

CARB-X, led by Boston University, is funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the United States Department of Health and Human Services, the Wellcome Trust in the United Kingdom, and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The UK Government’s Department of Health and Social Care (DHSC), through its Global Antimicrobial Resistance Innovation Fund (GAMRIF) has been a CARB-X funding partner since May 2018. The Bill and Melinda Gates Foundation, the world’s largest foundation dedicated to improving the quality of life for individuals around the world, is a CARB-X Alliance Partner since May 2018. Germany’s Federal Ministry of Education and Research (BMBF) has been a funding partner since March 2019. With funds from its Funding and Alliance Partners, CARB-X is investing more than US$500 million from 2016-2021 to accelerate the development of innovative antibiotics and other therapeutics, vaccines, and rapid diagnostics to address drug-resistant bacterial infections.

Business, technical and scientific support for CARB-X-funded product developers is provided in partnership with CARB-X’s Global Accelerator Network.


UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners


BARDA is a core component of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR). BARDA draws on its extensive experience of successfully advancing promising medical countermeasures through late-stage development. BARDA is providing CARB-X with up to $250 million during the 2016-2021 program.

Wellcome Trust

Wellcome Trust is one of the world’s leading funders of biomedical R&D, with significant experience and commitment in antibacterial R&D. Wellcome is funding CARB-X with up to $155 million to CARB-X between 2016-2021. Tim Jinks and Ed Whiting represent the Wellcome Trust on the JOC.

Germany’s Federal Ministry of Education and Research (BMBF)

Education and research are the foundations for our future. The promotion of education, science and research by Germany’s Federal Ministry of Education and Research (BMBF) represents an important contribution to securing Germany’s prosperity. Education and research are a German Federal Government policy priority, which is reflected in the development of the funding it is making available to these fields. BMBF is funding CARB-X with €39 million over four years.


NIAID is a US Government agency and is a key funder to protect against emerging infectious diseases, including antimicrobial resistance. NIAID commits in-kind services (e.g. preclinical services) to projects supported by CARB-X over five years and retains key governance roles.Dennis Dixon and Ann Eakin represent NIAID on the JOC.

The UK Government’s Department of Health and Social Care (DHSC), Global Antimicrobial Resistance Innovation Fund (GAMRIF)

The Department for Health and Social Care (DHSC) is the UK Government department which is responsible for helping people to live more independent, healthier lives for longer. The partnership with CARB-X is part of DHSC’s Global Antimicrobial Resistance Innovation Fund (GAMRIF). GAMRIF was established to provide seed funding for innovative research and development, specifically in neglected and underinvested areas, to address the threat of AMR. GAMRIF is a £50m UK aid investment, which means all projects funded must support research which is primarily and directly for the benefit of people in low- and middle-income countries (LMICs).

Bill & Melinda Gates Foundation

The Bill & Melinda Gates Foundation is a major funder of global health R&D. The foundation is partnering with CARB-X to advance the development of vaccines and novel biologics to avert drug-resistant diseases and protect the lives of vulnerable populations in low- and middle-income countries.